Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy.

Xue, Song; Gafita, Andrei; Dong, Chao; Zhao, Yu; Tetteh, Giles; Menze, Bjoern H; Ziegler, Sibylle; Weber, Wolfgang; Afshar-Oromieh, Ali; Rominger, Axel; Eiber, Matthias; Shi, Kuangyu (2022). Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy. European journal of nuclear medicine and molecular imaging, 49(12), pp. 4064-4072. Springer 10.1007/s00259-022-05883-w

[img]
Preview
Text
Xue2022_Article_ApplicationOfMachineLearningTo.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

PURPOSE

Although treatment planning and individualized dose application for emerging prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) are generally recommended, it is still difficult to implement in practice at the moment. In this study, we aimed to prove the concept of pretherapeutic prediction of dosimetry based on imaging and laboratory measurements before the RLT treatment.

METHODS

Twenty-three patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA I&T RLT were included retrospectively. They had available pre-therapy 68 Ga-PSMA-HEBD-CC PET/CT and at least 3 planar and 1 SPECT/CT imaging for dosimetry. Overall, 43 cycles of 177Lu-PSMA I&T RLT were applied. Organ-based standard uptake values (SUVs) were obtained from pre-therapy PET/CT scans. Patient dosimetry was calculated for the kidney, liver, spleen, and salivary glands using Hermes Hybrid Dosimetry 4.0 from the planar and SPECT/CT images. Machine learning methods were explored for dose prediction from organ SUVs and laboratory measurements. The uncertainty of these dose predictions was compared with the population-based dosimetry estimates. Mean absolute percentage error (MAPE) was used to assess the prediction uncertainty of estimated dosimetry.

RESULTS

An optimal machine learning method achieved a dosimetry prediction MAPE of 15.8 ± 13.2% for the kidney, 29.6% ± 13.7% for the liver, 23.8% ± 13.1% for the salivary glands, and 32.1 ± 31.4% for the spleen. In contrast, the prediction based on literature population mean has significantly larger MAPE (p < 0.01), 25.5 ± 17.3% for the kidney, 139.1% ± 111.5% for the liver, 67.0 ± 58.3% for the salivary glands, and 54.1 ± 215.3% for the spleen.

CONCLUSION

The preliminary results confirmed the feasibility of pretherapeutic estimation of treatment dosimetry and its added value to empirical population-based estimation. The exploration of dose prediction may support the implementation of treatment planning for RLT.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Xue, Song, Afshar Oromieh, Ali, Rominger, Axel Oliver, Shi, Kuangyu

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1619-7089

Publisher:

Springer

Language:

English

Submitter:

Pubmed Import

Date Deposited:

01 Jul 2022 09:31

Last Modified:

05 Dec 2022 16:21

Publisher DOI:

10.1007/s00259-022-05883-w

PubMed ID:

35771265

Uncontrolled Keywords:

177Lu-PSMA I&T Dosimetry Machine learning Radioligand therapy Treatment planning

BORIS DOI:

10.48350/171029

URI:

https://boris.unibe.ch/id/eprint/171029

Actions (login required)

Edit item Edit item
Provide Feedback